In 2018, a randomized controlled clinical trial (the E-LIFT trial) conducted in India on 50 patients with T2DM and NAFLD showed that the addition of empagliflozin 10 mg to standard T2DM therapy for 20 weeks resulted in a significant reduction (16.2% vs. 11.3%) in liver fat at the end of treatment, as measured by proton density MRI, and an improvement in serum ALT levels [82]. Here, GPT is linked to type 2 diabetes mellitus.